Gri Bio, Inc. (GRI)
NASDAQ:GRI
GRI Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GRI Stock 12 Month Forecast
Average Price Target
$25.00
▲(8828.57% Upside)
| Highest Price Target$40.00 | Average Price Target$25.00 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Ascendiant
$1,008→$40
Buy
14185.71%
Upside
Reiterated
03/10/26
We are adjusting our 2026 estimates for EPS to $(6.10) from $(76). We are initiating our 2027 EPS estimate of $(5.41) GRI-0621: The company’s initial main focus is developing GRI-0621 for the treatment of IPF (Idiopathic Pulmonary Fibrosis). GRI-0621 is designed to reset the dysfunctional immune response driving disease by inhibiting the activity of iNKT cells, as opposed to targeting a symptom of the disease. In December 2023, the company commenced enrollment for its with IPF. This trial will be a twelve-week, multicenter, multinational, randomized, placebo-controlled trial in approximately 36 patients with IPF.
H.C. Wainwright
$280→$10
Buy
3471.43%
Upside
Reiterated
03/06/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Ascendiant
$1,008→$40
Buy
14185.71%
Upside
Reiterated
03/10/26
We are adjusting our 2026 estimates for EPS to $(6.10) from $(76). We are initiating our 2027 EPS estimate of $(5.41) GRI-0621: The company’s initial main focus is developing GRI-0621 for the treatment of IPF (Idiopathic Pulmonary Fibrosis). GRI-0621 is designed to reset the dysfunctional immune response driving disease by inhibiting the activity of iNKT cells, as opposed to targeting a symptom of the disease. In December 2023, the company commenced enrollment for its with IPF. This trial will be a twelve-week, multicenter, multinational, randomized, placebo-controlled trial in approximately 36 patients with IPF.
H.C. Wainwright
$280→$10
Buy
3471.43%
Upside
Reiterated
03/06/26
Best Analysts Covering GRI Bio
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
-9.66%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -9.66% per trade.
1 Year
Success Rate
0/8 ratings generated profit
Average Return
-80.06%
reiterated a buy rating last month
Copying Matthew Keller's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.06% per trade.
2 Years
xxx
Success Rate
0/8 ratings generated profit
Average Return
-81.16%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -81.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GRI Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
2
1
2
2
Buy
0
0
0
0
0
Hold
1
26
58
85
68
Sell
0
4
20
34
34
Strong Sell
0
7
7
7
0
total
4
39
86
128
104
Each month's total comprises the sum of three months' worth of ratings.
GRI Financial Forecast
GRI Stock Forecast FAQ
What is GRI’s average 12-month price target, according to analysts?
Based on analyst ratings, Gri Bio, Inc.’s 12-month average price target is 25.00.
What is GRI’s upside potential, based on the analysts’ average price target?
Gri Bio, Inc. has 8828.57% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GRI a Buy, Sell or Hold?
Gri Bio, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Gri Bio, Inc.’s price target?
The average price target for Gri Bio, Inc. is 25.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 8828.57% Increase from the current price of $0.28.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 8828.57% Increase from the current price of $0.28.
What do analysts say about Gri Bio, Inc.?
Gri Bio, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of GRI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.